Setrobuvir

Research use only, not for human use.

Setrobuvir (ANA-598) is an orally active non-nucleoside HCV NS5B polymerase inhibitor with inhibitory effects on de novo RNA synthesis and primer extension with IC50s between 4 and 5 nM.

Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition.

Setrobuvir (ANA598) is a non-nucleoside inhibitor that binds to the palm pocket of the HCV polymerase and has an EC50 against HCV genotype 1b/Con1-containing subgenomic replicons in the nanomolar range. Setrobuvir appears to inhibit both de novoinitiated RNA synthesis and primer extension, and its activity is unchanged by the presence of mutations that modify the activity of thumb-binding non-nucleoside inhibitors.

——

——

Others

Other Targets

SARS-CoV | DNA/RNA Synthesis | HCV Protease

——

——

1071517-39-9

560.62

C25H25FN4O6S2

>98% (HPLC)

——

C(N1[C@@]2([C@@]([C@@]3(C[C@]2(CC3)[H])[H])(C(O)=C(C1=O)C=4NC=5C(S(=O)(=O)N4)=CC(NS(C)(=O)=O)=CC5)[H])[H])C6=CC=C(F)C=C6

——

(-20℃)

With Ice Pack

≥ 2 years